Letters to the Editor

Warfarin and beetroot

Aust Prescr 2016;39:32 http://dx.doi.org/10.18773/austprescr.2016.017

The recent Letter to the Editor about warfarin and beetroot by Louise Vanpraag and the response from Philip Tideman and colleagues' both miss the point about warfarin and beetroot. It is commonplace for those eating beetroot to have red urine (beeturia) or red faeces, or both, and such symptoms in those taking warfarin can be worrying. On many occasions, warfarin dosage has been adjusted unnecessarily and there have been many unnecessary urinary and bowel investigations. The beetroot-induced symptoms are of no importance and of course can occur in anyone eating beetroot.

John Raven Clinical haematologist Consultant physician Bunbury, Qld

REFERENCES

 Vanpraag L. Warfarin and beetroot [letter]. Aust Prescr 2015;38:150. http://dx.doi.org/10.18773/ austprescr.2015.061

Philip A Tideman, Rosy Tirimacco, Andrew St John and Gregory W Roberts, the authors of the article, comment:

This is an excellent point, and any counselling regarding the signs of bleeding should include alerting the patient to the possibility of red or pink urine or faeces after eating beetroot. Likewise, clinicians should enquire about beetroot consumption for any patient presenting with pink or red urine or faeces.

Warfarin, St John's wort and INR

Aust Prescr 2016;39:32-3 http://dx.doi.org/10.18773/austprescr.2016.025

In regards to the article on the management of warfarin therapy,¹ the statement on page 46 'drugs that may increase INR – macrolide antibiotics, imidazole antifungals, sulfamethoxazole/ trimethoprim, amiodarone, statins, some nonsteroidal anti-inflammatory drugs and some complementary medicines such as St John's wort' may not be correct. In the literature, St John's wort *decreases* the INR through induction of cytochrome P450 (CYP)-mediated metabolism of warfarin and increases warfarin clearance.²⁻⁹

Angela Cattanach Siboniso Sibindi Clinical pharmacists Lismore Base Hospital Lismore, NSW

REFERENCES

- Tideman PA, Tirimacco R, St John A, Roberts GW. How to manage warfarin therapy. Aust Prescr 2015;38:44-8. http://dx.doi.org/10.18773/ austprescr.2015.016
- Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, et al. Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004;57:592-9. http://dx.doi.org/ 10.1111/j.1365-2125.2003.02051.x
- Jiang X, Blair EY, McLachlan AJ. Investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach. J Clin Pharmacol 2006;46:1370-8. http://dx.doi.org/10.1177/0091270006292124
- Yue QY, Bergquist C, Gerdén B. Safety of St John's wort (*Hypericum perforatum*). Lancet 2000;355:576-7. http://dx.doi.org/10.1016/S0140-6736(05)73227-X
- Zhou S, Chan E, Pan SQ, Huang M, Lee EJ. Pharmacokinetic interactions of drugs with St John's wort. J Psychopharmacol 2004;18:262-76. http://dx.doi.org/10.1177/0269881104042632
- Anticoagulants + Herbal medicines; St John's wort (*Hypericum perforatum*). In: Baxter K, editor. Stockley's Drug Interactions. London: RPS Publishing; 2015. www.medicinescomplete.com/mc [cited 2016 Mar 1]
- Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74. http://dx.doi.org/ 10.1016/S0163-7258(96)00140-4
- Moore LB, Goodwin B, Jones SA, Wisely GB, Serabjit-Singh CJ, Willson TM, et al. St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 2000;97:7500-2. http://dx.doi.org/10.1073/ pnas.130155097
- Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St. John's wort and theophylline. Ann Pharmacother 1999;33:502. http://dx.doi.org/10.1345/aph.18252

Gregory Roberts, one of the authors of the article, comments:

Thank you for pointing out the error in the article.¹ St John's wort induces CYP enzymes with a resultant increase in warfarin clearance and decrease in INR, not a possible increase in INR as described in the article. Decreases of 20% in AUC (area under the curve) have been noted in single warfarin dose studies,² so while prudent INR monitoring should be undertaken, the interaction is likely to be of clinically minor importance.

4

The Editorial Executive Committee welcomes letters. which should be less than 250 words. Before a decision to publish is made, letters which refer to a published article may be sent to the author for a response. Any letter may be sent to an expert for comment. When letters are published, they are usually accompanied in the same issue by any responses or comments. The Committee screens out discourteous inaccurate or libellous statements. The letters are sub-edited before publication. Authors are required to declare any conflicts of interest. The Committee's decision on publication is final.